ClinicalTrials.Veeva

Menu
Cullman Clinical Trials | Cullman, AL logo

Cullman Clinical Trials | Cullman, AL

Research site

Site insights

Top conditions

Top treatments

Bimagrumab
Cenicriviroc
Naltrexone Hydrochloride
Bupropion Hydrochloride
AZD7442
AXA1125
Semaglutide
Zotatifin
SNG001
LY3437943

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

9 of 30 total trials

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of m...

Enrolling
Seasonal Influenza
Biological: Fluarix®
Biological: Influsplit®

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prev...

Enrolling
Acute Gastroenteritis
Norovirus Acute Gastroenteritis
Biological: mRNA-1403
Biological: Placebo

This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (...

Enrolling
Obesity
Drug: Matching Placebo-Garetosmab
Drug: Garetosmab

The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 recep...

Active, not recruiting
Obesity
Muscle Loss
Drug: Semaglutide
Drug: Enobosarm

A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).

Enrolling
Obesity
Drug: Placebo
Drug: Naltrexone-Bupropion (NB) Combination

A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and...

Active, not recruiting
Overweight or Obesity
Obese
Drug: Semaglutide
Biological: Bimagrumab

The purpose of this study is to select a dose of CD388 that is effective in preventing symptomatic laboratory-confirmed influenza infections, as comp...

Enrolling
Influenza
Combination Product: CD388 Injection
Combination Product: Placebo

This Phase 2, randomized, observer-blind clinical study is evaluating 3 different priming and booster regimens with MF59-adjuvanted H5N8 and/or H5N6...

Active, not recruiting
Influenza, Human
Infection Viral
Biological: aH5N6c on Day 1
Biological: aH5N8c on Day 22

Trial sponsors

Moderna logo
Exact Sciences Corporation logo
Lilly logo
L
Pfizer logo
A
Bristol-Myers Squibb (BMS) logo
C
C
D

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems